Entities / Company
Humacyte (United States).
company in Morrisville, United States
- Reports this week
- 0
- Active events
- 0
- Connections
- 30
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
One to three months ago
Gone quiet
No new reports in 90+ days-
Gavril Yushvaev was reported as a shareholder in Humacyte on June 22, 2025.Speculative1 report
-
On June 26, 2025, the Medical sector gain outperformed Humacyte's stock drop, with the cause traced to changes in the Zacks rating system.Speculative1 report
-
The FDA approved an expansion of hospital eligibility for Humacyte's Symvess drug.Well supported5 reports
-
Humacyte's stock performance led the Medical sector gain on July 26, 2025, though it lagged the S&P 500's daily gain.Some support3 reports
-
On August 7, 2025, Humacyte was noted to be underperforming the losses of the broader medical sector, with its stock performance lagging the S&P 500's daily gains.Some support2 reports
-
FDA approved ATEV for vascular trauma indication.Some support1 report
-
ABR called for buying Humacyte, Inc. on August 20, 2025.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Humacyte (United States) this week
News at the entities that move Humacyte (United States) most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Humacyte (United States)
-
Incepta Pharmaceuticals Shared contextTilray Brands, Inc.'s stock change lagged the S&P 500 gain on August 28, 2025, while the company holds a Zacks Rank of #3.Moves Humacyte (United States)
Connections
The 2 strongest of 30, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
The FDA formally regulates and grants approval for pharmaceutical products and applications developed by Humacyte.
-
Incepta Pharmaceuticals Shared context
Both Incepta Pharmaceuticals and Humacyte operate within the broader medical sector.
History
Events by the month they beganJune 2026
8 events- Humacyte announced its company results from Durham, North Carolina.
- Gavril Yushvaev was reported as a shareholder in Humacyte on June 22, 2025.
- On June 26, 2025, the Medical sector gain outperformed Humacyte's stock drop, with the cause traced to changes in the Zacks rating system.
- The FDA approved an expansion of hospital eligibility for Humacyte's Symvess drug.
- Humacyte's stock performance led the Medical sector gain on July 26, 2025, though it lagged the S&P 500's daily gain.
- On August 7, 2025, Humacyte was noted to be underperforming the losses of the broader medical sector, with its stock performance lagging the S&P 500's daily gains.
- FDA approved ATEV for vascular trauma indication.
- ABR called for buying Humacyte, Inc. on August 20, 2025.